Escitalopram Treatment In Acute Stroke (ESTIAS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01561092|
Recruitment Status : Withdrawn (Study medication could not be supplied. An alternative project will be conducted)
First Posted : March 22, 2012
Last Update Posted : June 19, 2012
Growing international scientific evidence has indicated a positive effect of SSRI treatment (serotonin reuptake inhibitors) after stroke, beyond its antidepressant effect. We wish to conduct a prospective randomised double blind placebo-controlled multicenter study of the combined neuroprotective and antithrombotic effects of SSRI treatment after stroke. Deletion of the SERT (serotonin transporter) gene may influence this treatment effect and may in itself be a risk factor for stroke, an aspect we also wish to explore.
- SSRI treatment commenced in the acute phase of stroke (day 2-5) protects against new thromboembolic events and leads to better rehabilitation.
- A specific SERT genotype is associated with an increased risk of first ever stroke.
- A specific SERT genotype is associated with a higher risk of post stroke depression.
600 stroke patients will be randomised to either escitalopram or placebo treatment in a 1:1 ratio and genotyped according to SERT polymorphisms. The treatment and follow up period is 6 months. During these 6 months there will be 2 clinical follow up visits, one telephone control and one visit to evaluate compliance regarding medication. Patients who had an MRI as a part of the routine investigations done upon admission (approximately 300 patients) will have a control MRI after 6 months.
Additionally 400 patients, not eligible for participation i the randomised controlled trial, will be genotyped and answer questionnaires after 1 and 6 months.
|Condition or disease||Intervention/treatment||Phase|
|Stroke||Drug: Escitalopram Drug: Placebo||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Efficacy of Escitalopram Treatment in Acute Stroke and the Role of SERT Genotype in Stroke|
|Active Comparator: Escitalopram||
5 or 10 mg escitalopram tablets administered orally once daily
|Placebo Comparator: Non active drug||
- New vascular events [ Time Frame: 6 months ]
- Death of any cause [ Time Frame: 6 months ]
- Myocardial Infarction [ Time Frame: 6 months ]
- Re-stroke [ Time Frame: 6 months ]
- Motor function [ Time Frame: 6 months ]Fugl-Meyer Motor score is performed
- White Matter lesions [ Time Frame: 6 months ]Evaluated on MRI
- Bleeding complications [ Time Frame: 6 months ]
- Combined vascular death [ Time Frame: 6 months ]
- Cognitive abilities [ Time Frame: 6 months ]SDMT and MMSE tests are performed
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01561092
|Neurology Department, Aalborg Hospital|
|Aalborg, Denmark, 9000|
|Neurology Department, University Hospital of Aarhus|
|Aarhus, Denmark, 8000|
|Neurology Department, Glostrup Hospital|
|Glostrup, Denmark, 2600|
|Principal Investigator:||Grethe Andersen, Prof. DMSc||University Hospital of Aarhus, Neurology Dept.|